Authors
Kathrin Halfter, Anne Schlesinger-Raab, Dieter Hölzel
Published in
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Volume 53. Issue 2. Pages 112372. Nov 13, 2026. Epub Nov 13, 2026.
Abstract
Earlier detection and timely, guideline-adherent treatment have substantially improved breast cancer outcomes. However, the time between diagnosis and treatment is increasing. Untreated invasive breast cancer remains biologically active, and observational studies associate longer delay intervals with less favourable outcomes. Recommendations for upper limits may be misinterpreted as a safe waiting period. Current evidence does not establish a precise threshold beyond which harm begins, nor does it prove that every reduction of a few days improves survival. This paper argues that time to initial treatment should be regarded as a clinically relevant and modifiable component of breast cancer care. The pre-treatment pathway, including the intervals required for diagnostic clarification, the treatment decision-to-initiation interval, and the reasons for prolonged waiting times, should be documented and analysed. We propose standardized documentation of relevant dates, reporting of waiting-time distributions, classification of reasons for delay, and explicit monitoring of organisationally modifiable intervals. How is the time between diagnosis and treatment used, and can delays without clinical benefit be systematically reduced?
PMID:
43051066
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0